Investigational subcutaneous pembrolizumab and berahyaluronidase alfa, in combination with chemotherapy, demonstrates noninferior pharmacokinetics compared to intravenous KEYTRUDA in combination with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback